A5067563308- CAR-T cell therapy research
- Reproductive System and Pregnancy
- Immune Cell Function and Interaction
- Viral Infectious Diseases and Gene Expression in Insects
- Immunotherapy and Immune Responses
- Biosimilars and Bioanalytical Methods
- T-cell and B-cell Immunology
- Virus-based gene therapy research
- Monoclonal and Polyclonal Antibodies Research
- Endometriosis Research and Treatment
- Reproductive Biology and Fertility
- Erythrocyte Function and Pathophysiology
- Reproductive Physiology in Livestock
- Ectopic Pregnancy Diagnosis and Management
- Pregnancy and Medication Impact
- Cutaneous lymphoproliferative disorders research
- Phagocytosis and Immune Regulation
- RNA Interference and Gene Delivery
- Pregnancy and preeclampsia studies
- Immunodeficiency and Autoimmune Disorders
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
Theravectys (France)
2020-2024
Commissariat à l'Énergie Atomique et aux Énergies Alternatives
2005-2015
Infectious Disease Models and Innovative Therapies
2015
Paris Biotech Santé
2015
Hôpital Saint-Louis
2005-2011
Institut d'Imagerie Biomédicale
2011
Background CAR-T cells immunotherapy is a breakthrough in the treatment of hematological malignancies such as acute lymphoblastic leukemia (ALL) and B-cell malignancies. However, therapies face major hurdles lack tumor-specific antigen (TSA), immunosuppressive tumor microenvironment sometimes caused by tumorous expression immune checkpoints (ICPs) HLA-G. Indeed, HLA-G remarkable because it both potent ICP TSA. causes escape impairing innate adaptive responses inducing suppressive...
Human telomerase reverse transcriptase (hTERT) is overexpressed in more than 85% of human cancers regardless their cellular origin. As immunological tolerance to hTERT can be overcome not only spontaneously but also by vaccination, it represents a relevant universal tumor associated antigen (TAA). Indeed, specific cytotoxic T lymphocyte (CTL) precursors are present within the peripheral T-cell repertoire. Consequently, vaccine an attractive candidate for antitumor immunotherapy. Here,...
Abstract The acquisition by T cells of exogenous ligands originally expressed APC has been already described. However, reports essentially focused on the outward signaling acquired and their effects surroundings cells. We investigated function transferred receptors (not ligands) that them they interact with). show inhibitory Ig-like transcript 2 efficiently transfer from monocytes to autologous trogocytosis integrate within plasma membrane acquirer Furthermore, can access compatible...
Trogocytosis is the transfer of plasma membrane fragments and molecules they contain between one donor acceptor/acquirer cell. Through trogocytosis, acceptor cells temporarily display use cell-surface do not express themselves, but borrow from other cells. Here, we investigated whether liquid tumors possessed a trogocytic capability, if immune escape could be acquired by tumor cells, transferred same tumor, this benefit as whole.For this, trogocytosis in hematological cell lines freshly...
HLA-G is a natural tolerogenic molecule involved in the best example of tolerance to foreign tissues there is: maternal-fetal tolerance. The further involvement allogeneic transplants has also been demonstrated and some its mechanisms action have elucidated. For these reasons, therapeutic molecules for induction transplantation are actively investigated. In present study, we studied functions three different recombinant proteins: heavy chain fused β2-microglobulin (B2M), B2M Fc portion an...
Nonclassical human leukocyte antigen (HLA) class I molecule HLA-G and indoleamine 2,3 dioxygenase (INDO) in humans mice, respectively, have been shown to play crucial immunosuppressive roles fetal-maternal tolerance. inhibits natural killer T cell function by high-affinity interaction with inhibitory receptors, INDO acts depleting the surrounding microenvironment of essential amino acid tryptophan, thus inhibiting proliferation. We investigated whether expression were linked. Working...
Invariant Natural Killer T (iNKT) cells are a small and distinct population of crucial in immunomodulation. After activation by alpha-GalactosylCeramide (αGC), an exogenic glycolipid antigen, iNKT can rapidly release cytokines to enhance specific anti-tumor activity. Several human clinical trials on cell-based anti-cancer ongoing, however results not as striking murine models. Given that iNKT-based immunotherapies dependent mainly antigen-presenting (APC), tolerogenic molecule with no...
Chimeric antigen receptor (CAR) T cells express an extracellular domain consisting of a single-chain fragment variable (scFv) targeting surface tumor-associated antigen. scFv selection should involve safety profiling with evaluation the efficacy/toxicity balance, especially when target also is expressed on healthy cells. Here, to assess differences in terms efficacy and on-target/off-tumor effects, we generated five different CARs CD123 by substituting only scFv. In vitro models, engineered...
<div>Abstract<p>Chimeric antigen receptor (CAR) T cells express an extracellular domain consisting of a single-chain fragment variable (scFv) targeting surface tumor-associated antigen. scFv selection should involve safety profiling with evaluation the efficacy/toxicity balance, especially when target also is expressed on healthy cells. Here, to assess differences in terms efficacy and on-target/off-tumor effects, we generated five different CARs CD123 by substituting only scFv....
<div>Abstract<p>Chimeric antigen receptor (CAR) T cells express an extracellular domain consisting of a single-chain fragment variable (scFv) targeting surface tumor-associated antigen. scFv selection should involve safety profiling with evaluation the efficacy/toxicity balance, especially when target also is expressed on healthy cells. Here, to assess differences in terms efficacy and on-target/off-tumor effects, we generated five different CARs CD123 by substituting only scFv....
<p>Supplementary Figure S2: Characterization of CD123 CAR-T.</p>
<p>Supplementary Figure S3: Effect of CD123 CAR-T on human Hematopoietic stem cell.</p>
<p>Supplementary Figure S1: Design of five CD123 CAR-T constructs.</p>
<p>Supplementary Figure S4 Effect of CD123 CAR-T on humanized mouse model, NSG-SGM3.</p>
<p>Supplementary Figure S3: Effect of CD123 CAR-T on human Hematopoietic stem cell.</p>
<p>Supplementary Figure S2: Characterization of CD123 CAR-T.</p>
<p>Supplementary Figure S4 Effect of CD123 CAR-T on humanized mouse model, NSG-SGM3.</p>